← Alle Unternehmen
Über das Unternehmen
Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse the multi-organ complications arising from liver cirrhosis. It was shown to be safe and well tolerated in a Ph1b study with positive efficacy outcomes, and is now ready to start Phase 2a clinical investigations. VS-01 was granted orphan drug designations by the FDA and EMA, which help streamlining its clinical development pathway.